Tarsus Pharmaceuticals
TARS
157 hedge funds and large institutions have $1.43B invested in Tarsus Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 58 increasing their positions, 34 reducing their positions, and 6 closing their positions.
683% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 6
107% more capital invested
Capital invested by funds: $692M → $1.43B (+$738M)
74% more call options, than puts
Call options by funds: $7.46M | Put options by funds: $4.29M
71% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 34
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
35% more funds holding
Funds holding: 116 → 157 (+41)
1.76% more ownership
Funds ownership: 103.11% → 104.86% (+1.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$54.1M |
| 2 |
Jennison Associates
New York
|
+$39.1M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$24.2M |
| 4 |
BCM
Boone Capital Management
Atlanta,
Georgia
|
+$17.9M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
+$14.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$44.6M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$35.8M |
| 3 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
-$10.3M |
| 4 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$10.3M |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$6.61M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FFA
151
Farther Finance Advisors
San Francisco,
California
| $430 | – | – | – |
|
|
RAM
152
Riggs Asset Management
Dallas,
Pennsylvania
| $364 | +$294 | +10 | New |
|
|
RIL
153
Rothschild Investment LLC
Chicago,
Illinois
| $182 | +$147 | +5 | New |
|
|
AWM
154
Avior Wealth Management
Omaha,
Nebraska
| $181 | +$147 | +5 | New |
|
|
HNB
155
Huntington National Bank
Columbus,
Ohio
| $36 | -$44.1K | -1,500 | -100% |
|
156
Point72 Asset Management
Stamford,
Connecticut
| – | -$396K | -19,575 | Closed |
|
|
BCM
157
Bayesian Capital Management
Brooklyn,
New York
| – | -$312K | -15,400 | Closed |
|
|
OC
158
Oppenheimer & Co
New York
| – | -$285K | -14,056 | Closed |
|
159
Mirae Asset Global Investments
Seoul,
South Korea
| – | -$227K | -11,226 | Closed |
|
160
American Century Companies
Kansas City,
Missouri
| – | -$224K | -11,075 | Closed |
|
161
Comerica Bank
Dallas,
Texas
| – | -$1.15K | -57 | Closed |
|
162
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$59 | +2 | New |
|
|
C
163
Covestor
London,
United Kingdom
| – | +$88 | +3 | New |
|
TARS Hedge Fund Activity: Q1 2024 in Review
157 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Tarsus Pharmaceuticals (TARS) for Q1 2024, worth a combined $1.43B — up 107% from $692M a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new TARS positions and 6 closed out — a net gain of 41 holders — while 58 added to existing stakes and 34 trimmed.
The largest buyer was Paradigm Biocapital Advisors, adding an estimated $54.1M. The largest seller was Morgan Stanley, cutting an estimated $44.6M.
- 157 institutional investors held Tarsus Pharmaceuticals (TARS) as of Q1 2024, up from 116 in Q4 2023.
- Funds reported $1.43B of Tarsus Pharmaceuticals stock for Q1 2024, up 107% quarter-over-quarter.
- 47 funds opened new Tarsus Pharmaceuticals positions in Q1 2024 and 6 closed out, a net change of +41 holders.
- The largest Tarsus Pharmaceuticals buyer in Q1 2024 was Paradigm Biocapital Advisors, an estimated $54.1M added.
- The largest Tarsus Pharmaceuticals seller in Q1 2024 was Morgan Stanley, an estimated $44.6M sold.
Based on aggregated 13F filings for Q1 2024.